lamotrigine has been researched along with Child Behavior Disorders in 9 studies
Child Behavior Disorders: Disturbances considered to be pathological based on age and stage appropriateness, e.g., conduct disturbances and anaclitic depression. This concept does not include psychoneuroses, psychoses, or personality disorders with fixed patterns.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blinded, placebo-controlled, crossover study, 61 children with well-controlled or mild epilepsy were randomly assigned to add-on therapy with either lamotrigine followed by placebo or placebo followed by lamotrigine." | 5.11 | Treatment of interictal epileptiform discharges can improve behavior in children with behavioral problems and epilepsy. ( Binnie, CD; Pressler, RM; Robinson, RO; Wilson, GA, 2005) |
| "An 8-year-old boy developed tremor, unsteadiness, chorea, and eye movement abnormalities on starting lamotrigine for myoclonic jerks." | 3.72 | Unusual side effects of lamotrigine therapy. ( Cross, JH; Das, KB; Harris, C; Smyth, DP, 2003) |
| "Epilepsy was diagnosed in 54." | 1.62 | The molecular and phenotypic spectrum of CLCN4-related epilepsy. ( Cao, D; Fahlke, C; Guzman, RE; He, H; Peng, J; Sierra-Marquez, J; Stauber, T; Yin, F, 2021) |
| "Lamotrigine was used concurrently in four of the 11 children with behavioral or cognitive abnormalities but in only seven of the 64 children without abnormalities (P = 0." | 1.31 | Factors associated with behavioral and cognitive abnormalities in children receiving topiramate. ( Connolly, MB; Farrell, K; Gerber, PE; Hamiwka, L, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| He, H | 1 |
| Guzman, RE | 1 |
| Cao, D | 1 |
| Sierra-Marquez, J | 1 |
| Yin, F | 1 |
| Fahlke, C | 1 |
| Peng, J | 1 |
| Stauber, T | 1 |
| Shinnar, RC | 1 |
| Shinnar, S | 1 |
| Cnaan, A | 1 |
| Clark, P | 1 |
| Dlugos, D | 1 |
| Hirtz, DG | 1 |
| Hu, F | 1 |
| Liu, C | 1 |
| Masur, D | 1 |
| Weiss, EF | 1 |
| Glauser, TA | 1 |
| Huber-Mollema, Y | 1 |
| Oort, FJ | 1 |
| Lindhout, D | 1 |
| Rodenburg, R | 1 |
| Das, KB | 1 |
| Harris, C | 1 |
| Smyth, DP | 1 |
| Cross, JH | 1 |
| Pressler, RM | 1 |
| Robinson, RO | 1 |
| Wilson, GA | 1 |
| Binnie, CD | 1 |
| Gilbert, DL | 1 |
| Buncher, CR | 1 |
| Zesiewicz, TA | 1 |
| Sullivan, KL | 1 |
| Hauser, RA | 1 |
| Manonmani, V | 1 |
| Wallace, SJ | 1 |
| Gerber, PE | 1 |
| Hamiwka, L | 1 |
| Connolly, MB | 1 |
| Farrell, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study[NCT00088452] | Phase 3 | 453 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 35 |
| Lamotrigine | 25 |
| Valproic Acid | 52 |
Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 12 months of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 70 |
| Lamotrigine | 31 |
| Valproic Acid | 64 |
Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 81 |
| Lamotrigine | 43 |
| Valproic Acid | 85 |
2 trials available for lamotrigine and Child Behavior Disorders
| Article | Year |
|---|---|
Pretreatment behavior and subsequent medication effects in childhood absence epilepsy.
Topics: Adolescent; Anticonvulsants; Checklist; Child; Child Behavior Disorders; Child, Preschool; Cross-Ove | 2017 |
Treatment of interictal epileptiform discharges can improve behavior in children with behavioral problems and epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child Behavior Disorders; Cross-Over Studies; Double-Blind Metho | 2005 |
7 other studies available for lamotrigine and Child Behavior Disorders
| Article | Year |
|---|---|
The molecular and phenotypic spectrum of CLCN4-related epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child Behavior Disorders; Child, Preschool; Chlorid | 2021 |
Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child Behavior Disorders; Epilepsy; Female; Humans; La | 2019 |
Unusual side effects of lamotrigine therapy.
Topics: Anticonvulsants; Child; Child Behavior Disorders; Chorea; Cognition Disorders; Epilepsy, Absence; Hu | 2003 |
Epileptiform discharges and the behavior of children with epilepsy.
Topics: Anticonvulsants; Child; Child Behavior Disorders; Electroencephalography; Epilepsy; Humans; Lamotrig | 2006 |
Chorea induced by lamotrigine.
Topics: Anticonvulsants; Child; Child Behavior Disorders; Chorea; Electroencephalography; Epilepsies, Myoclo | 2006 |
Epilepsy with myoclonic absences.
Topics: Anticonvulsants; Brain; Child; Child Behavior Disorders; Child, Preschool; Electroencephalography; E | 1994 |
Factors associated with behavioral and cognitive abnormalities in children receiving topiramate.
Topics: Adolescent; Anticonvulsants; Child; Child Behavior Disorders; Child, Preschool; Cognition Disorders; | 2000 |